REZLIDHIA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rezlidhia, and what generic alternatives are available?
Rezlidhia is a drug marketed by Rigel Pharms and is included in one NDA. There are thirteen patents protecting this drug.
This drug has one hundred and four patent family members in thirty-seven countries.
The generic ingredient in REZLIDHIA is olutasidenib. One supplier is listed for this compound. Additional details are available on the olutasidenib profile page.
DrugPatentWatch® Generic Entry Outlook for Rezlidhia
Rezlidhia will be eligible for patent challenges on December 1, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 1, 2029. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for REZLIDHIA?
- What are the global sales for REZLIDHIA?
- What is Average Wholesale Price for REZLIDHIA?
Summary for REZLIDHIA
| International Patents: | 104 |
| US Patents: | 13 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 29 |
| Patent Applications: | 31 |
| Drug Prices: | Drug price information for REZLIDHIA |
| What excipients (inactive ingredients) are in REZLIDHIA? | REZLIDHIA excipients list |
| DailyMed Link: | REZLIDHIA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for REZLIDHIA
Generic Entry Date for REZLIDHIA*:
Constraining patent/regulatory exclusivity:
TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for REZLIDHIA
REZLIDHIA is protected by thirteen US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of REZLIDHIA is ⤷ Sign Up.
This potential generic entry date is based on TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting REZLIDHIA
Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS ACUTE MYELOID LEUKEMIA (AML)
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF TREATING ACUTE MYELOID LEUKEMIA (AML) IN PATIENTS WITH AN ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF TREATING ACUTE MYELOID LEUKEMIA (AML) IN PATIENTS WITH AN ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF TREATING ACUTE MYELOID LEUKEMIA (AML) IN PATIENTS WITH AN ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF TREATING AN ADULT PATIENT WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA HAVING A SUSCEPTIBLE IDH1 MUTATION
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF TREATING A CANCER WHERE THE CANCER IS ACUTE MYELOID LEUKEMIA (AML)
FDA Regulatory Exclusivity protecting REZLIDHIA
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rigel Pharms | REZLIDHIA | olutasidenib | CAPSULE;ORAL | 215814-001 | Dec 1, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Rigel Pharms | REZLIDHIA | olutasidenib | CAPSULE;ORAL | 215814-001 | Dec 1, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Rigel Pharms | REZLIDHIA | olutasidenib | CAPSULE;ORAL | 215814-001 | Dec 1, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Rigel Pharms | REZLIDHIA | olutasidenib | CAPSULE;ORAL | 215814-001 | Dec 1, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for REZLIDHIA
When does loss-of-exclusivity occur for REZLIDHIA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 1976
Patent: DERIVADOS DE PIRIDIN-2(1H)-ON QUINOLINONA COMO INHIBIDORES DE ISOCITRATO DESHIDROGENASA MUTANTE
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 15317322
Patent: Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Estimated Expiration: ⤷ Sign Up
Patent: 15317327
Patent: Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Estimated Expiration: ⤷ Sign Up
Patent: 15317329
Patent: Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Estimated Expiration: ⤷ Sign Up
Patent: 19283765
Patent: Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Estimated Expiration: ⤷ Sign Up
Patent: 21215141
Patent: Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2017005238
Patent: derivados de piridin-2(1h)-ona quinolinona como inibidores da isocitrato desidrogenase mutante
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 61807
Patent: DERIVES DE PHENYLQUINOLEINONE EN TANT QU'INHIBITEURS D'ISOCITRATE DESHYDROGENASE MUTANTE (PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 61811
Patent: DERIVE DE PYRIDINYLQUINOLINONE EN TANT QU'INHIBITEURS DE L'ISOCITRATE DESHYDROGENASE MUTANTE (PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 61817
Patent: DERIVES DE PYRIDIN-2-(1H)-ONE-QUINOLINONE A TITRE D'INHIBITEURS D'ISOCITRATE DESHYDROGENASE MUTANTE (PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 17000658
Patent: Derivados de piridin-2(1h)-ona quinolinona como inhibidores de isocitrato deshidrogenasa mutante
Estimated Expiration: ⤷ Sign Up
China
Patent: 7001328
Patent: 作为突变型异柠檬酸脱氢酶抑制剂的吡啶‑2(1H)‑酮喹啉酮衍生物 (Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors)
Estimated Expiration: ⤷ Sign Up
Patent: 1909130
Patent: 作为突变型异柠檬酸脱氢酶抑制剂的吡啶-2(1H)-酮喹啉酮衍生物 (Pyridine-2(1H)-one quinolinone derivatives as mutant isocitrate dehydrogenase inhibitors)
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 17003241
Patent: Derivados de piridin-2(1h)-on quinolinona como inhibidores de isocitrato deshidrogenasa mutante
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0182176
Estimated Expiration: ⤷ Sign Up
Patent: 0200666
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 21149
Estimated Expiration: ⤷ Sign Up
Patent: 22865
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 94376
Estimated Expiration: ⤷ Sign Up
Patent: 47050
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 17022933
Patent: DERIVADOS DE PIRIDIN-2 (1H)-ON QUINOLINONA COMO INHIBIDORES DE ISOCITRATO DESHIDROGENASA MUTANTE
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 4336
Patent: ХИНОЛИНОНОВЫЕ ПРОИЗВОДНЫЕ ПИРИДИН-2(1H)-ОНА КАК ИНГИБИТОРЫ МУТАНТНОЙ ИЗОЦИТРАТДЕГИДРОГЕНАЗЫ (PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 8574
Patent: ХИНОЛИНОНОВЫЕ ПРОИЗВОДНЫЕ ПИРИДИН-2(1H)-ОНА И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ (PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF)
Estimated Expiration: ⤷ Sign Up
Patent: 1790657
Patent: ХИНОЛИНОНОВЫЕ ПРОИЗВОДНЫЕ ПИРИДИН-2(1H)-ОНА КАК ИНГИБИТОРЫ МУТАНТНОЙ ИЗОЦИТРАТДЕГИДРОГЕНАЗЫ
Estimated Expiration: ⤷ Sign Up
Patent: 1992489
Patent: ХИНОЛИНОНОВЫЕ ПРОИЗВОДНЫЕ ПИРИДИН-2(1H)-ОНА КАК ИНГИБИТОРЫ МУТАНТНОЙ ИЗОЦИТРАТДЕГИДРОГЕНАЗЫ
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 94375
Patent: DÉRIVÉS DE PHÉNYLQUINOLÉINONE EN TANT QU'INHIBITEURS D'ISOCITRATE DÉSHYDROGÉNASE MUTANTE (PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 94376
Patent: DÉRIVÉS DE PYRIDIN-2-(1H)-ONE-QUINOLINONE À TITRE D'INHIBITEURS D'ISOCITRATE DÉSHYDROGÉNASE MUTANTE (PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 01185
Patent: DÉRIVÉ DE PYRIDINYLQUINOLINONE EN TANT QU'INHIBITEURS DE L'ISOCITRATE DÉSHYDROGÉNASE MUTANTE (PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 47050
Patent: DÉRIVÉS DE PYRIDIN-2-(1H)-ONE-QUINOLINONE EN TANT QU'INHIBITEURS D'ISOCITRATE DÉSHYDROGÉNASE (PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 33662
Patent: DÉRIVÉS DE PYRIDIN-2-(1H)-ONE-QUINOLINONE EN TANT QU'INHIBITEURS D'ISOCITRATE DÉSHYDROGÉNASE (PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 57131
Patent: DÉRIVÉS DE PYRIDIN-2-(1H)-ONE-QUINOLINONE EN TANT QU'INHIBITEURS D'ISOCITRATE DÉSHYDROGÉNASE (PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Finland
Patent: 33662
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 41460
Estimated Expiration: ⤷ Sign Up
Patent: 62424
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 1163
Patent: תולדות פירידין-2(1h)-און קווינולינון כמעכבי דהידרוגנאז מוטנט-איזוציטרט (Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors)
Estimated Expiration: ⤷ Sign Up
Patent: 2363
Patent: תולדות פירידין-2(1h)-און קווינולינון כמעכבי דהידרוגנאז מוטנט-איזוציטרט (Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors)
Estimated Expiration: ⤷ Sign Up
Patent: 2608
Patent: תולדות פירידין-2(1h)-און קווינולינון כמעכבי דהידרוגנאז מוטנט-איזוציטרט (Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 48115
Estimated Expiration: ⤷ Sign Up
Patent: 51081
Estimated Expiration: ⤷ Sign Up
Patent: 20836
Estimated Expiration: ⤷ Sign Up
Patent: 17528487
Patent: 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジン−２（１Ｈ）−オンキノリノン誘導体
Estimated Expiration: ⤷ Sign Up
Patent: 17528489
Patent: 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのフェニルキノリノン誘導体
Estimated Expiration: ⤷ Sign Up
Patent: 17528491
Patent: 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジニルキノリノン誘導体
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 94376
Estimated Expiration: ⤷ Sign Up
Patent: 47050
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 6250
Patent: PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
Patent: 7533
Patent: PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 17003404
Patent: DERIVADOS DE PIRIDIN-2(1H)-ONA QUINOLINONA COMO INHIBIDORES DE ISOCITRATO DESHIDROGENASA MUTANTE. (PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS.)
Estimated Expiration: ⤷ Sign Up
Patent: 17003626
Patent: DERIVADOS DE PIRIDINIL QUINOLINONA COMO INHIBIDORES DE ISOCITRATO DESHIDROGENASA MUTANTE (MT-IDH). (PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS.)
Estimated Expiration: ⤷ Sign Up
Patent: 17003637
Patent: DERIVADOS DE FENIL QUINOLINONA COMO INHIBIDORES DE ISOCITRATO DESHIDROGENASA MUTANTE (MT-IDH). (PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS.)
Estimated Expiration: ⤷ Sign Up
Patent: 19013203
Patent: DERIVADOS DE PIRIDIN-2(1H)-ONA QUINOLINONA COMO INHIBIDORES DE ISOCITRATO DESHIDROGENASA MUTANTE. (PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS.)
Estimated Expiration: ⤷ Sign Up
Montenegro
Patent: 776
Patent: DERIVATI PIRIDIN-2(1H)-ON HINOLINONA KAO INHIBITORI MUTIRANE IZOCITRAT DEHIDROGENAZE (PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 481
Patent: DÉRIVÉS DE PYRIDIN-2-(1H)-ONE-QUINOLINONE À TITRE D'INHIBITEURS D'ISOCITRATE DÉSHYDROGÉNASE MUTANTE
Estimated Expiration: ⤷ Sign Up
Patent: 064
Patent: DÉRIVÉS DE PYRIDIN-2-(1H)-ONE-QUINOLINONE EN TANT QU'INHIBITEURS D'ISOCITRATE DÉSHYDROGÉNASE
Estimated Expiration: ⤷ Sign Up
Patent: 352
Patent: DÉRIVÉS DE PYRIDIN-2-(1H)-ONE-QUINOLINONE EN TANT QU'INHIBITEURS D'ISOCITRATE DÉSHYDROGÉNASE
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 0373
Patent: Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 171056
Patent: DERIVADOS DE PIRIDIN-2(1H)-ON QUINOLINONA COMO INHIBIDORES DE ISOCITRATO DESHIDROGENASA
Estimated Expiration: ⤷ Sign Up
Philippines
Patent: 017500517
Patent: PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 94376
Estimated Expiration: ⤷ Sign Up
Patent: 47050
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 94376
Estimated Expiration: ⤷ Sign Up
Patent: 47050
Estimated Expiration: ⤷ Sign Up
Patent: 33662
Estimated Expiration: ⤷ Sign Up
Saudi Arabia
Patent: 7381129
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 184
Patent: DERIVATI PIRIDIN-2(1H)-ON HINOLINONA KAO INHIBITORI MUTIRANE IZOCITRAT DEHIDROGENAZE (PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 140
Patent: DERIVATI PIRIDIN-2(1H)-ON HINOLINONA KAO INHIBITORI MUTIRANE IZOCITRAT DEHIDROGENAZE (PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 201702194S
Patent: PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 94376
Estimated Expiration: ⤷ Sign Up
Patent: 47050
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1702127
Patent: PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
Patent: 1902446
Patent: PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 2209667
Estimated Expiration: ⤷ Sign Up
Patent: 170063742
Patent: 돌연변이-아이소시트레이트 탈수소효소 저해제로서의 피리딘-2(1H)-온 퀴놀린 유도체 (- -21H- PYRIDIN-21H-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 04897
Estimated Expiration: ⤷ Sign Up
Patent: 06525
Estimated Expiration: ⤷ Sign Up
Patent: 06888
Estimated Expiration: ⤷ Sign Up
Patent: 90640
Estimated Expiration: ⤷ Sign Up
Patent: 53347
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 86390
Estimated Expiration: ⤷ Sign Up
Patent: 1617335
Patent: Pyridin-2(1H)-one quinolinone derivatives as mutant-ISO citrate dehydrogenase inhibitors
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering REZLIDHIA around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
